Foresee Pharmaceuticals Co Ltd (6576) — Cash Flow-to-Debt Ratio
Foresee Pharmaceuticals Co Ltd (6576) has a Cash Flow-to-Debt Ratio of -0.27x as of June 2025, meaning its operating cash flow of NT$-157.53 Million could theoretically repay 0% of its total liabilities (NT$593.99 Million) in one year. Check 6576 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Foresee Pharmaceuticals Co Ltd Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Foresee Pharmaceuticals Co Ltd across 8 annual periods. Also explore Foresee Pharmaceuticals Co Ltd (6576) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Foresee Pharmaceuticals Co Ltd (2017–2024)
Year-by-year debt coverage analysis for Foresee Pharmaceuticals Co Ltd. For market capitalisation and broader financial context, see Foresee Pharmaceuticals Co Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.10x | NT$-1.17 Billion | NT$560.15 Million | ▼ -45.7% |
| 2023 | -1.44x | NT$-887.55 Million | NT$616.93 Million | ▼ -142.7% |
| 2022 | -0.59x | NT$-233.22 Million | NT$393.43 Million | ▲ +10.7% |
| 2021 | -0.66x | NT$-213.33 Million | NT$321.26 Million | ▲ +73.4% |
| 2020 | -2.50x | NT$-674.80 Million | NT$270.40 Million | ▲ +36.8% |
| 2019 | -3.95x | NT$-447.82 Million | NT$113.40 Million | ▼ -7.6% |
| 2018 | -3.67x | NT$-462.43 Million | NT$125.99 Million | ▲ +24.5% |
| 2017 | -4.86x | NT$-483.10 Million | NT$99.44 Million | — |